Financial Results for the quarter ended 31st December 2025.

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.1%Reaction day

₹33.60

prior close

₹35.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.7%+3.8% vs market

Pharmaceuticals peers, median of 154sector-0.5%+3.6% vs sector

On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 3.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.1-0.7+3.8-0.5+3.6

Next day

+0.6+0.2+0.3-0.0+0.6

-0.0+0.5-0.6+0.0-0.0

-1.8-0.9-0.9-0.8-1.0

-2.2-1.0-1.1-1.4-0.8

-5.4-0.9-4.5-0.9-4.5

-9.3-2.0-7.4-2.0-7.3

15d

-8.6-6.9-1.7-4.9-3.7

-12.2-10.5-1.7-7.1-5.1

-14.6+1.5-16.2-0.2-14.4

-29.3+3.8-33.2+2.7-32.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kabra Drugs Ltd reported strong results for Q3 FY26, with revenue from operations at ₹3,042 lakhs, up sharply from ₹715 lakhs in Q3 FY25 (a jump of over 4x year-on-year). Net profit for the quarter stood at ₹256.65 lakhs (EPS ₹1.08), compared to a loss of ₹49.98 lakhs (EPS negative ₹0.21) in the same quarter last year. For the nine months ended December 2025, the company posted a revenue of ₹5,733.40 lakhs and a net profit of ₹390.34 lakhs, turning around from a loss of ₹147.85 lakhs in the corresponding nine-month period of the previous year. The statutory auditors issued an unqualified limited review report with no qualifications or matters of concern. The company also noted that paid-up share capital increased during the year (from ₹1,007.91 lakhs to ₹2,370.79 lakhs), indicating a possible stock split or bonus issue.

Likely market impact

The company has moved firmly into profitability with a sharp jump in revenue and bottom-line, which is positive for shareholders. Clean audit review and no flagged risks support a constructive short-term view, though investors should track sustainability of this revenue surge.